Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25645560 | 0.82 | NCF1 (0.39) | NPC1NCF1CHRM1HRH3CHRM2 | |
| SCHEMBL12049582 | 0.80 | NPC1 (0.42) | NPC1NCF1CHRM1HRH3CHRM2 | |
| SCHEMBL22597889 | 0.78 | NCF1 (0.41) | NPC1NCF1CHRM1HRH3CHRM2 | |
| SCHEMBL791729 | 0.78 | NPC1 (0.41) | NPC1NCF1CHRM1HRH3CHRM2 | |
| SCHEMBL3425518 | 0.78 | NPC1 (0.41) | NPC1NCF1CHRM1HRH3CHRM2 | |
| SCHEMBL23970916 | 0.78 | NCF1 (0.46) | NPC1NCF1CHRM1HRH3CHRM2 | |
| SCHEMBL17873709 | 0.78 | — | — | |
| SCHEMBL25571582 | 0.77 | NPC1 (0.64) | NPC1NCF1CHRM1HRH3CHRM2 | |
| SCHEMBL6603242 | 0.77 | GNAI3 (0.43) | NPC1NCF1CHRM1HRH3CHRM2 | |
| SCHEMBL6603236 | 0.77 | GNAI3 (0.43) | NPC1NCF1CHRM1HRH3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024003533-A1 | PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2024-01-04 | — | — | WO | disclosed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | NPC1 2674/4885NCF1 770/4885CHRM1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.